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Abstract: Although vascular abnormalities are thought to affect coronavirus disease 2019 (COVID-
19) patients’ outcomes, they have not been thoroughly characterized in large series of unselected
patients. The Swiss national registry coronavirus-associated vascular abnormalities (CAVA) is a
multicentric cohort of patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
infection who underwent a clinically indicated chest computed tomography (CT) aiming to assess
the prevalence, severity, distribution, and prognostic value of vascular and non-vascular-related
CT findings. Clinical outcomes, stratified as outpatient treatment, inpatient without mechanical
ventilation, inpatient with mechanical ventilation, or death, will be correlated with CT and biological
markers. The main objective is to assess the prevalence of cardiovascular abnormalities–including
pulmonary embolism (PE), cardiac morphology, and vascular congestion. Secondary objectives
include the predictive value of cardiovascular abnormalities in terms of disease severity and fatal
outcome and the association of lung inflammation with vascular abnormalities at the segmental level.
New quantitative approaches derived from CT imaging are developed and evaluated in this study.
Patients with and without vascular abnormalities will be compared, which is supposed to provide
insights into the prognostic role and potential impact of such signs on treatment strategy. Results are
expected to enable the development of an integrative score combining both clinical data and imaging
findings to predict outcomes.
Keywords: COVID-19; computed tomography; perfusion; pulmonary embolism; vascular congestion;
respiratory failure
1. Introduction
A subset of patients infected with severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) will develop pneumonia and severe disease [1,2], challenging healthcare
providers because the physiopathological mechanisms are unsatisfactorily understood.
Hypoxemia leading to mechanical ventilation may be the consequence of several factors, of
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which thromboembolism is emerging as a key component since blood hypercoagulability
is common among hospitalized patients with coronavirus disease 2019 (COVID-19) [3–7].
Since the SARS-CoV-2 outbreak, computed tomography (CT) imaging has almost
immediately established itself as the primary non-invasive test for diagnosis, monitor-
ing of COVID-19 pneumonia, and complications thereof, including deep-learning-based
analysis [8–14].
While most of the currently available literature relies on non-contrast CT [10,15], the
need to assess vascular abnormalities is being recognized as an increasingly important fac-
tor [16–19], both to help distinguish COVID-19 pneumonia from other viral infections and
to exclude pulmonary embolism (PE). Acute PE is believed to be a significant contributory
factor in patients with adverse outcomes [3,6,7,20], and anticoagulation therapy was found
to reduce mortality in severe COVID-19 disease [21].
Although vascular involvement is thought to aggravate COVID-19 morbidity and
mortality, there are still unresolved issues regarding the nature and impact of cardiovas-
cular abnormalities. Furthermore, no convincing theory helps understand the interaction
between virus-induced inflammatory disorders and morphologic changes, especially those
observed on CT. In addition, the severity of hypoxemia in COVID-19 patients seems to be
related to more complex mechanisms than morphologic damages observed in CT [22].
The prevalence of PE in unselected patients is still debated regarding thromboem-
bolic complications. Clot burden/distribution (anatomic distribution, relationship to
ground-glass opacity, and clinical severity) is yet to define. Moreover, the association
between PE and important clinical variables lack, including time from onset, severity, age
of patients, risk factors for venous thromboembolic disease (VTD), and anticoagulation
prophylaxis regimen.
Recently vascular changes other than PE have drawn attention [23]. Additional
knowledge is, however, required and not yet available to confirm and better understand
early observations. In particular, a radiological sign referred to as “vascular thickening”,
“vascular enlargement”, or “vascular congestion” (VC) that is thought to be a specific
marker of COVID-19 pneumonia calls for a thorough assessment. Quantitative analysis
of this sign and correlation to clinical presentation is highly desirable and may help
understand its pathophysiology [24].
Most valuable information to address these open issues will likely come from severely
ill patients and those who die since a recent autopsy study reports thromboembolism in
50% of people who died from COVID-19, emphasizing the critical role of PE in adverse
outcomes [25].
Consequently, we probably underestimate the role of vascular changes and complica-
tions induced directly or indirectly by the coronavirus. Seeking a better understanding of
the disease is undoubtedly a step toward better managing COVID-19 and its cardiovascu-
lar complications.
2. Methods and Analysis
2.1. Study Design
This study aims to explore COVID-19 features on CT with specific regard to vascu-
lar changes.
The data and the conclusions of this study could enhance the clinical care, risk stratifi-
cation, and, ultimately, clinical outcomes of patients affected with severe COVID-19.
Specifically, this multicenter observational study is designed to comprehensively
picture the spectrum of vascular findings related to COVID-19 pneumonia and find corre-
lations with outcomes.
To this end, we will analyze lung parenchymal findings in patients with COVID-19
infection, including their relationship to vascular changes. Vascular abnormalities will
be subdivided into PE and non-PE-related lesions. Qualitative interpretation by expert
cardiothoracic radiologists and state-of-the-art quantitative analyses will be conducted,
including computer-based assessment.
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2.1.1. Primary Objective
The study aims to describe the prevalence of vascular abnormalities in COVID-19
pneumonia, especially PE.
2.1.2. Secondary Objectives
Secondary objectives include the frequency of various other factors (as described
hereafter) and their potential impact on outcome or treatment.
We will measure the frequency of specific vascular abnormalities related or not to PE
and compare their prevalence.
2.2. Patient Selection
Patients will be recruited in six Swiss university-affiliated institutions from five cantons
(Basel, Bern, Geneva, Vaud, Zurich). For this purpose, each center needs to screen hundreds
of COVID-19 patients to select those who meet the inclusion criteria and do not have any
exclusion criteria.
2.2.1. Inclusion Criteria
Patients admitted for COVID-19 (with positive reverse transcription polymerase chain
reaction for SARS-CoV-2) who had a chest CT within the specified timeframe.
2.2.2. Exclusion Criteria
Age less than 18 years, patients with another pre-existing infectious process, non-
optimal CT scan or incomplete CT data, documented refusal of the reuse of medical data.
2.2.3. Sample Size Calculation
The sample size estimate is based on the primary objective of the study. We assume
that PE-positive patients have clots in two lung segments on average; the sample size
is designed for 80% power and a type-one error rate of 5% [26]. Under the hypothesis
that macroscopic PE is related to a systemic hypercoagulability status and does not result
from in situ thrombosis due to alveolar inflammation, the probability of an embolus to be
located in a segment with vs. without alveolar opacity should be roughly 50-50. To reject
this hypothesis and determine a statistically significantly higher incidence of PE in lung
segments with alveolar inflammation (20% increase, from 50% to 70%), we need to analyze
182 lung segments with PE. In other words, we need to enroll 91 patients with PE; since the
literature reports a PE incidence of 20% in COVID-19 pneumonia [27], we need to enroll at
least 500 patients with COVID-19 taking into account a safety margin for excluded patients
and those who have declined to participate. By recruiting patients in the most prominent
centers in Switzerland, we may reach 1000 patients with COVID-19 pneumonia, of which
around 20% will also have PE.
3. Methodology and Data Analysis
We will retrieve clinical, laboratory, and imaging data of eligible patients. Demo-
graphic data, including age and sex composition, will be analyzed. Intra-hospital medical
records, laboratory test results, and data from chest CT performed in the participating
centers will be collected in a Research Electronic Data Capture (REDCap)-based multicenter
registry. The study flowchart is reported in Figure 1.
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Figure 1. Study flowchart.
3.1. CT Analysis
CT Scans Are Analyzed to Identify:
- PE related abnormalities: the presence of embolic material, anatomic distribution
based on segmental arteries, parenchymal changes and their distribution (PE present
in the region of interest subject of parenchymal changes induced by the coronavirus),
presence of perfusion defect–using iodine vs. water material decomposition if dual-
energy CT was performed–assessment of right ventricle, left atrium, and pulmonary
artery dimensions (diameters), and quantification of vascular obstruction using the
Qanadli obstruction index (QOI) [28,29] and a modified Qanadli obstruction index
(mQOI) based on the segmental analysis as follows:
mQOI = (
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quantification of vascular volumes and tissue volumes, quantification of venous
dilatation, and arterial enlargement.
- Non-vascular abnormalities include ground-glass opacities, consolidation, cysts, nod-
ules, and pleural changes. Semi-quantitative assessment of SARS-CoV-2-related
opacities is provided per segment: alveolar opacities (none, <50%, >50%) and per
patient. A new relative volume-based index is calculated as follows:
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ROI: region of interest with parenchymal changes
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Finally, predictive modeling will be performed to deri e an integrative sc re account-
ing for both cli ical variables an imagin fi dings o classify the disease severity bette
and predict patient out omes.
3.2. Data Management
All data will be coded and gathered using REDCap, a Human Research Act (HRA)-
compliant electronic data collection platform [30]. REDCap is a secure, web-based platform
providing data collection and management in research.
3.3. Statistical Analysis
For statistical analysis, we will conduct correlation analysis with Spearman’s rank test,
group comparison of qualitative data with Wilcoxon signed-rank test, group comparison
of quantitative data with Pearson’s Chi-square test. The inter-observer agreement will
be measured by Cohen’s Kappa test for ordinal data and with the intra-class correlation
coefficient for continuous data. Outcome modeling will be performed using logistic
regression analysis.
Collected data and variables under evaluation are summarized in Tables 1 and 2.
Depending on the evolution of this worldwide pandemic and increasing knowledge con-
cerning new drugs to manage COVID-19 pneumonia, e.g., tamoxifen [31], an amendment
might be submitted to the Ethics Committee to analyze additional variables.
Table 1. Clinical and laboratory data to be collected.
Variable Data Variable Type
Disease severity Outpatient, inpatient, death Qualitative
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Table 1. Cont.
Onset to CT delay Number of days Ordinal
Onset to recovery delay Number of days Ordinal
Thromboprophylaxis or anticoagulants Qualitative Dichotomic
D-dimers Plasma concentration Continuous
PaO2 Arterial blood partial pressure Continuous
SaO2 Venous blood O2 saturation Continuous
C-reactive protein Plasma concentration Continuous
Thrombocytes Count per microliter Integer
Table 2. Imaging variables under test.
Variable Data Variable Type Segment Lung Patient
Left atrium size 2 axes, continuous Continuous x
Right ventricle (RV) Small axis Continuous x
Left ventricle (LV) Small axis Continuous x
Pulmonary artery (PA) Diameter Continuous x
Vascular congestion (VC) Qualitative Dichotomic x x x
Vascular volume (VV) Volumetric Continuous x x
Perfusion (PF) Qualitative, iodine density map Ordinal (decreased,normal, increased x x
Venous-to-artery ratio (VRR) Diameter ratio Continuous x x x
Pulmonary embolism (PE) Qualitative Dichotomic x x x
Qanadli obstruction
index (QOI) Percentage Ordinal (0–100% in 2.5% steps) x x x
Modified QOI (mQOI) Percentage Ordinal (0–100% in 2.5% steps) x x x
Ground glasses
opacities (GGO) Qualitative Dichotomic x x x
Alveolar consolidation Qualitative Dichotomic x x x
Cyst Qualitative Dichotomic x x x
Nodule Qualitative Dichotomic x x x
Lung tissue volume (TV) Volumetric Continuous x x
4. Discussion and Clinical Relevance
While most of the currently available literature relies on non-contrast CT, the need
to assess vascular abnormalities is being recognized as an increasingly important factor,
both to help distinguish COVID-19 pneumonia from other viral infections and to exclude
pulmonary embolism (PE). Acute PE is believed to be a significant contributory factor in
patients with adverse outcomes.
The nature of blood clots (arterial thrombosis versus arterial embolism) in the context
of COVID-19 is currently debated [32]. Because of this, one of the most critical analyses
we will conduct is to assess whether pulmonary blood clots are systematically associated
with signs of pneumonia (in the same lung segment) and shed light on the mechanisms
underlying vascular changes. Moreover, the association between unfavorable outcomes
and alveolar opacities and/or PE will be an essential result for a better insight into the
disease course.
Arterial thrombosis in COVID-19 may be due to inflammatory cytokines (suggestive
of PE), endothelial dysfunction, or hypoxia (suggestive of local thrombosis). Likewise, VC
can be linked to hyperemia in the context of lung inflammation or other factors such as in
situ venous thrombosis or vasodilatation triggered by cytokines. A better understanding of
these processes would support decision-making, specifically regarding the use and dosing
of anticoagulation therapy in severe COVID-19.
Several factors might potentially limit this study. First, some relevant biological
markers of cytokine storm, such as interleukin 6 (IL-6), are not routinely collected in all
centers and are not expected to be available for analysis. Second, a common pitfall is linked
to the enrollment process; since this study only considers patients with microbiologically
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proven SARS-CoV-2 infection for inclusion, a potentially significant proportion of patients
will remain undetected and excluded from the analysis. However, since the endpoints are
mainly related to patients with serious or severe disease, the impact should be limited.
Finally, should the data fail to offer a predictive value concerning patient outcomes, we may
need to review the data and elucidate if potential confounders influence the main effect.
5. Ethics and Dissemination
The study protocol was submitted through the Swiss Business Administration System
for Ethics Committee (BASEC) and approved by the independent Cantonal ethics com-
mittees in charge. All procedures will be conducted by the leading institution (Lausanne
University Hospital) and participating institutions (Bern, Zurich, Basel, and Geneva Uni-
versity Hospitals) under the Federal Act on Research involving Human Beings (Human
Research Act, HRA). The study will be conducted in compliance with the protocol, the
current version of the Declaration of Helsinki, the International Conference on Harmoniza-
tion Good Clinical Practices (ICH-GCP), and other locally relevant legal and regulatory
requirements. Baseline patients characteristics, primary and secondary outcomes will be
published in scientific peer-reviewed journals.
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